CCS-Pfizer ATTR-CM Research Fellowship Award
The Canadian Cardiovascular Society (CCS) and Pfizer have collaboratively created a research fellowship award as part of the CCS Research Fellowships and Awards Program entitled “CCS-Pfizer ATTR-CM Research Fellowship Award.” This is a salary award where the purpose is to foster the growth of peer-reviewed Canadian research in the area of Transthyretin Amyloid Cardiomyopathy (ATTR-CM), with a focus on excellence and support for early career Canadian researchers familiar with diagnosing and treating patients with ATTR-CM who are looking to establish an independent research career.
Call for Applications: Closed
- Be a CCS Member*. For more information about CCS Membership, visit the CCS website: https://ccs.ca/en/membership.
*You must be a CCS member to accept funding, but you can apply without being a member!
- Applicants must be a Canadian Citizen or Permanent Resident of Canada at the time funding is received.
- The principal investigator must have completed an MD degree (or equivalent) and have obtained a fellowship from the Royal College of Physicians & Surgeons of Canada (or equivalent from a foreign country) or from the Canadian College of Family Physicians; or have completed a PharmD; or have completed a PhD (post-doc).
- Applicants must provide a letter of acceptance to a faculty or clinical position at a Canadian institution.
- Applicants must demonstrate support by the university or institution at which the applicant will conduct the proposed research program. Requirement for a statement completed by the Dean and Department Head (or institutional equivalents) demonstrating commitment of the university or institution to provide the applicant appropriate academic rank, time allocated to the proposed research program, and to provide adequate space and facilities for the investigator’s research, as well as a commitment to developing the applicant’s research, technical and professional skills and networks over the training period by providing career planning, skills development and networking opportunities to prepare the trainee for an impactful career.
- Applicants can be principal investigators on only one application.
- Award funds are solely intended for research performed in Canada.
- This salary award is intended for a Fellow to perform original research that is either clinical or translational with expected impact on patient care. Proposal should not request supplemental funding for a project that has extramural funding.
- If the submission refers to a multicenter clinical trial, the applicant must indicate their specific role in the research study.
- If the application is for a sub-study of an ongoing project or trial, the applicant must specify their role and explain how the sub-study is distinct from the main study.
- If funded, proposed research must be completed within 12 months (with consideration for projects up to 24 months) from the start of funding.
- Research status reports will be required on October 1st of every year that the project is running.
Eligible Areas of Research
Eligible research activities must involve clinical outcomes research or clinical research in an area related to ATTR-CM, which may include the study of early identification, evaluation, diagnosis, prognosis and management; use of screening tools and their impact on improvement of patient health.
Ineligible Areas of Research
- Head-to-head studies
- Any indications outside of TTR amyloidosis
- Pediatric investigations
- End stage disease
- Dose response studies
- Tafamidis Animal studies
A single salary award of $60,000 will be awarded to one individual based on an independent peer review process. Funding begins the summer of 2023 for 12 months.
The Peer Review Process
All applications will be pre-screened for eligibility. Applications that are late, incomplete and/or do not meet the basic eligibility criteria will not be considered for review. Peer review of all eligible applications will be conducted by a scientific review committee comprised of CCS members. The 2023 peer review committee members are Dr. Margot Davis, Dr. Nowell Fine, and Dr. Jonathan Howlett. All eligible proposals will be reviewed by at least two members of the peer review committee.
If you have any questions or require support preparing and submitting your application, please email email@example.com.
The Canadian Cardiovascular Society and Pfizer Canada are proud to support the CCS-Pfizer ATTR-CM Research Fellowship Award. With this award, we hope to support early career Canadian researchers familiar with diagnosing and treating patients with ATTR-CM who are looking to establish an independent research career.